Analyst firms · Citigroup · NVS
Citigroup NVS price target and rating history
Novartis AG (NVS) · Health Care
Citigroup rates Novartis AG (NVS) Buy, as of its latest action on Jan 27, 2026. It has published 3 rating actions on NVS since January 2022, including 0 upgrades and 1 downgrade.
- Current rating
- Buy
- Price target
- Not stated
- Median target, all firms
- Too few
- Actions on NVS
- 3
Every Citigroup rating on NVS
- Jan 27, 2026InitiateCitigroup starts coverage at Buy
- Jan 26, 2023
- Jan 10, 2022
How other firms rate NVS
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Deutsche Bank | Sell | Oct 30, 2026 | |
| HSBC | Hold | Sep 10, 2026 | |
| RBC Capital Markets | Sector Perform | Sep 9, 2026 | |
| Argus Research | Buy | $180 | Mar 11, 2026 |
| Citigroup | Buy | Jan 27, 2026 | |
| Barclays | Equal Weight | Jan 6, 2026 | |
| Morgan Stanley | Overweight | Dec 3, 2025 | |
| BofA Securities | Buy | Nov 25, 2025 |
Questions about Citigroup and NVS
- What is Citigroup's rating on NVS?
- Citigroup rates NVS Buy, a bullish rating, as of Jan 27, 2026.
- When did Citigroup last change its view on NVS?
- On Jan 27, 2026, Citigroup starts coverage at Buy.
More NVS rating histories
All Citigroup ratingsNVS news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.